Growth inhibition (50%) of the potent compounds against the NCI human cancer cell line panel.

Cancer	Sub panel	GI50 (μM)
		1c (R = 3-Br)	1b (R = 3-Cl)	1g (R = 4-OCH3)	1e (R = 4-Br)
Leukemia	CCRF-CEM	NTa	2.70	2.08	2.81
	HL-60(TB)	1.87	2.91	2.69	2.30
	K-562	1.93	2.41	2.71	2.24
	MOLT-4	2.29	3.83	2.21	2.86
	RPMI-8226	2.14	2.25	2.60	2.56
	SR	NT	NT	2.87	NT
Non-small cell lung	A549/ATCC	3.37	9.73	3.32	11.10
	EKVX	2.15	3.68	2.66	4.69
	HOP-62	3.78	15.30	3.44	18.90
	HOP-92	2.21	4.29	2.02	5.08
	NCI-H226	1.62	1.66	3.58	1.93
	NCI-H23	1.84	4.36	2.51	10.50
	NCI-H322M	5.09	10.40	4.71	12.50
	NCI-H460	2.43	8.87	1.91	12.60
	NCI-H522	1.90	1.75	2.49	2.08
Colon	COLO 205	2.18	4.85	1.95	4.45
	HCC-2998	1.87	3.49	2.87	9.11
	HCT-116	1.83	1.84	1.86	1.94
	HCT-15	1.66	1.79	2.53	1.97
	HT29	2.10	2.70	2.86	2.80
	KM12	2.44	3.29	2.38	7.17
	SW-620	2.22	2.35	2.29	2.33
CNS	SF-268	12.60	17.30	3.25	16.50
	SF-295	1.83	4.27	2.13	12.10
	SF-539	1.74	1.77	2.03	2.20
	SNB-19	2.45	2.41	1.75	7.04
	SNB-75	NT	NT	4.42	NT
	U251	1.81	2.15	2.77	6.83
Melanoma	LOX IMVI	1.39	1.44	1.73	1.37
	MALME-3M	1.93	1.84	1.74	3.98
	M14	2.52	2.19	3.14	3.40
	MDA-MB-435	3.40	2.47	2.24	3.24
	SK-MEL-2	2.55	2.71	3.97	5.85
	SK-MEL-28	1.93	1.98	2.54	2.13
	SK-MEL-5	1.75	2.27	1.52	1.04
	UACC-257	2.85	11.20	2.46	11.8
	UACC-62	1.55	1.69	1.68	3.44
Ovarian	IGROV1	2.72	4.15	3.98	13.80
	OVCAR-3	2.02	1.93	2.26	2.08
	OVCAR-4	4.47	4.40	2.96	5.02
	OVCAR-5	2.14	3.64	3.90	10.00
	OVCAR-8	1.88	2.39	3.34	3.24
	NCI/ADR-RES	1.75	1.93	NT	2.20
	SK-OV-3	5.80	16.00	10.50	16.80
Renal	786–0	1.92	3.36	1.92	5.75
	A498	2.08	1.85	17.00	16.80
	ACHN	1.95	2.47	3.52	2.16
	CAKI-1	2.77	4.00	2.96	8.18
	RXF 393	1.81	1.73	1.74	1.90
	SN12C	2.03	2.94	3.54	7.51
	TK-10	5.10	12.40	4.12	18.40
	UO-31	NT	NT	1.70	NT
Prostate	PC-3	3.07	4.08	2.98	4.08
	DU-145	3.08	5.01	3.23	8.24
Breast	MCF7	1.28	2.06	2.48	2.13
	MDA-MB-231/ATCC	NT	NT	2.39	NT
	HS 578T	5.27	9.04	2.20	17.70
	BT-549	1.44	2.36	2.36	2.88
	T-47D	NT	NT	3.25	NT
	MDA-MB-468	1.61	1.88	2.17	2.47

^aNT – not tested.